| __timestamp | Dynavax Technologies Corporation | Insmed Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 31073000 |
| Thursday, January 1, 2015 | 22180000 | 43216000 |
| Friday, January 1, 2016 | 37257000 | 50679000 |
| Sunday, January 1, 2017 | 27367000 | 79171000 |
| Monday, January 1, 2018 | 64770000 | 168218000 |
| Tuesday, January 1, 2019 | 74986000 | 210796000 |
| Wednesday, January 1, 2020 | 79256000 | 203613000 |
| Friday, January 1, 2021 | 100156000 | 234273000 |
| Saturday, January 1, 2022 | 131408000 | 265784000 |
| Sunday, January 1, 2023 | 152946000 | 344501000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, understanding financial health is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Insmed Incorporated and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Insmed's SG&A expenses surged by approximately 1,000%, reflecting its aggressive growth strategy. In contrast, Dynavax's expenses increased by about 760%, indicating a more measured expansion.
By 2023, Insmed's SG&A expenses reached nearly double those of Dynavax, highlighting its significant investment in administrative and sales functions. This trend suggests Insmed's focus on scaling operations and market presence. Meanwhile, Dynavax's steady rise in expenses points to a balanced approach, possibly prioritizing sustainable growth. These insights offer a window into the strategic priorities of these biotech firms, providing investors and stakeholders with valuable context for decision-making.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Dynavax Technologies Corporation
Comparing SG&A Expenses: Novartis AG vs Insmed Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Insmed Incorporated vs Sarepta Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Amneal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for Insmed Incorporated and Vericel Corporation
Who Optimizes SG&A Costs Better? Insmed Incorporated or Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Iovance Biotherapeutics, Inc.
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.